[Draft of Federal Register invention disclosures received early October 1996]
Plant Protein Useful For Treating Tumors And HIV Infection
Description of Invention:
MAP 30, a 30 kDa basic protein, which may be purified from Momordica charantia fruit or seed extracts or produced by recombinant DNA technology, is useful in treating HIV infection and cancer. M. charantia, commonly known as bitter melon, is a medicinal plant whose extracts have been used for centuries in China and Southeast Asia as antiinfection and antitumor agents. MAP 30 is capable of inhibiting HIV-1 infection in T lymphocytes and monocytes as well as replication of HIV-1 in infected cells, yet is not toxic to normal uninfected cells. The biological properties of MAP 30 include: (1) N-glycosidase activity on 28S ribosomal RNA; (2) topological activity on plasmid and viral DNAs including HIV-1 LTRs; and (3) dose-dependent inhibition of HIV-1 integrase. The cloning and expression of the gene encoding biologically active recombinant MAP30 provides an abundant source of homogeneous material for clinical investigations. The patent discloses purified natural and recombinant protein, processes for purifying the protein, DNA sequences encoding the protein, and recombinant methods for expressing the protein.
Inventors:
Sylvia Lee-Huang, et al.
Relevant Publications:
Lee-Huang, S., et al., "Proteolytic fragments of anti-HIV proteins MAP30 and GAP31 are biologically active," XI International Conference on AIDS (abstract)
Lee-Huang, S., et al., "Inhibition of the integrase of human immunodeficiency virus (HIV) by anti-HIV plant proteins MAP30 and GAP31," Proc. Natl. Acad. Sci. 92: 8818-8822 (1995)
Lee-Huang, S., et al., "Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon," Gene 161: 151-156 (1995)
Patent Status:
Serial No. 08/277,283 filed 21 Jul 94; U.S. Patent 5,484,889 issued 16 Jan 96
Foreign patent rights are available in Australia, Canada, Europe, and Japan
Related Cases:
Anti-HIV Proteins GAP 31, DAP 30 and DAP 32 and Therapeutic Uses Thereof
S Lee-Huang, et al.
U.S. Patent 5,317,009 issued 31 May 94
An Anti-HIV Protein, TAP 29, From Trichosanthes, DNA Coding Therefor and Therapeutic Uses Thereof
S Lee-Huang, et al.
Serial No. 08/275,327 filed 26 Oct 92
Portfolios:
Infectious Diseases - Therapeutics, anti-virals, AIDS
Cancer - Therapeutics, other
For additional information, please contact:
Elaine Gese, M.B.A.
Office of Technology Transfer
National Institutes of Health
6011 Executive Boulevard, Suite 325
Rockville, MD 20852-3804
Phone: 301/496-7056 ext. 282
Fax: 301/402-0220
Anti-HIV Proteins GAP 31, DAP 30 And DAP 32 And Therapeutic Uses Thereof
Description of Invention:
GAP 31, a 31 kDa protein, and DAP 30 and 32, 30 and 32 kDa proteins, respectively, which may be purified from extracts of Gelonium multiflorum (a medicinal plant) and Dianthus caryophyllus (carnation), respectively, or produced by recombinant DNA technology, are useful in treating HIV infection. GAP 31 also exhibits anti-tumor activity. These proteins belong to the family of single-chain ribosome-inactivating proteins (SCRIPS), which inactivate ribosomes in cell-free systems but are relatively nontoxic to intact cells. The biological properties of GAP 31 include: (1) N-glycosidase activity on 28S ribosomal RNA; (2) topological activity on plasmid and viral DNAs including HIV-1 LTRs; and (3) dose-dependent inhibition of HIV-1 integrase. The cloning and expression of the genes encoding biologically active recombinant GAP31, and DAP 30 and 32 provides an abundant source of homogeneous material for clinical investigations. The patent discloses purified natural and recombinant proteins, processes for purifying the proteins, DNA sequences encoding the proteins, and recombinant methods for expressing the proteins.
Inventors:
Sylvia Lee-Huang, et al.
Relevant Publications:
Lee-Huang, S., et al., "Proteolytic fragments of anti-HIV proteins MAP30 and GAP31 are biologically active," XI International Conference on AIDS (abstract)
Lee-Huang, S., et al., "Inhibition of the integrase of human immunodeficiency virus (HIV) by anti-HIV plant proteins MAP30 and GAP31," Proc. Natl. Acad. Sci. 92: 8818-8822 (1995)
Patent Status:
Serial No. 07/749,541 filed 26 Aug 91; U.S. Patent 5,317,009 issued 31 May 94
Foreign patent rights are available in Australia, Canada, Europe, and Japan
Related Cases:
Plant Protein Useful for Treating Tumors and HIV Infection
S Lee-Huang, et al.
U.S. Patent 5,484,889 issued 16 Jan 96
An Anti-HIV Protein, TAP 29, From Trichosanthes, DNA Coding Therefor and Therapeutic Uses Thereof
S Lee-Huang, et al.
Serial No. 08/275,327 filed 26 Oct 92
Portfolio:
Infectious Diseases - Therapeutics, anti-virals, AIDS
For additional information, please contact:
Elaine Gese, M.B.A.
Office of Technology Transfer
National Institutes of Health
6011 Executive Boulevard, Suite 325
Rockville, MD 20852-3804
Phone: 301/496-7056 ext. 282
Fax: 301/402-0220
An Anti-HIV Protein, TAP 29, From Trichosanthes, DNA Coding Therefor And Therapeutic Uses Thereof
Description of Invention:
TAP 29, a 29 kDA protein which may be purified from the root tuber of the plant Trichosanthes kirilowii or produced by recombinant DNA technology, is useful in treating HIV infection and also exhibits anti-tumor activity. TAP 29 is a single-chain ribosome-inactivating protein (SCRIP) which inactivates ribosomes in cell-free systems but is relatively nontoxic to intact cells. TAP 29 has anti-HIV activity equivalent to trichosanthin but has a lower in vitro toxicity with a therapeutic index of approximately 5000. The cloning and expression of the gene encoding biologically active recombinant TAP 29 provides an abundant source of homogeneous material for clinical investigations. The natural protein, the DNA coding therefore, an antibody specific therefore, a method for purifying the natural protein, and the recombinant protein are provided.
Inventors:
Sylvia Lee-Huang, et al.
Relevant Publications:
"TAP 29: An anti-human immunodeficiency virus protein from Trichosanthes kirilowii that is nontoxic to intact cells," Proc. Natl. Acad. Sci. 88: 6570 (1991)
"Plant proteins with antiviral activity against human immunodeficiency virus," in Natural Products as Antiviral Agents (C.K. Chu, ed., 1992)
Patent Status:
Serial No. 08/275,327 filed 26 Oct 92
Foreign patent rights are available in Australia, Canada, Europe, and Japan
Related Cases:
Plant Protein Useful for Treating Tumors and HIV Infection
S Lee-Huang, et al.
U.S. Patent 5,484,889 issued 16 Jan 96
Anti-HIV Proteins GAP 31, DAP 30 and DAP 32 and Therapeutic Uses Thereof
S Lee-Huang, et al.
U.S. Patent 5,317,009 issued 31 May 94
Portfolio:
Infectious Diseases - Therapeutics, anti-virals, AIDS
For additional information, please contact:
Elaine Gese, M.B.A.
Office of Technology Transfer
National Institutes of Health
6011 Executive Boulevard, Suite 325
Rockville, MD 20852-3804
Phone: 301/496-7056 ext. 282
Fax: 301/402-0220